Pearl Street Venture Funds
Pearl Street Venture Funds is a venture capital firm founded in 2003 and headquartered in Indianapolis, Indiana. The firm specializes in early-stage investments, particularly in the life sciences sector, focusing on biotechnology, pharmaceuticals, medical devices, and agri-bio. It actively seeks opportunities in therapeutic product companies that are developing advanced technologies. Pearl Street Venture Funds has a specific interest in supporting companies based in Indiana and is capable of acting as both a lead and co-investor. While it is currently fully invested and not making new investments, its commitment to delivering superior financial returns for its limited partners remains a core objective. The firm also maintains additional offices in Los Angeles, West Lafayette, San Diego, and Gaithersburg.
Toggle
Pre Seed Round in 2018
Toggle is a company based in the United States that specializes in robotics and automation solutions for the construction industry. It offers a robotics as a service (RaaS) platform specifically designed for assembling rebar cages used in reinforced concrete applications. Utilizing advanced two-arm robotic platforms and proprietary jig designs, Toggle's technology enables the construction of rebar structures directly from computer blueprints, allowing for precise and efficient pre-assembly services.
CoLucid Pharmaceuticals
Series C in 2015
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.
CoLucid Pharmaceuticals
Venture Round in 2011
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.
CoLucid Pharmaceuticals
Series B in 2008
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.
Serenex is a U.S.-based medical drug discovery and development company that specializes in oncology and related therapeutic areas. Founded in 2000 and acquired by Pfizer in 2008, Serenex has developed a proprietary Hsp90 product platform that includes a range of small molecule Hsp90 inhibitors targeting cancer, inflammatory diseases, fungal infections, viral diseases, and neurodegenerative conditions such as Alzheimer's. Additionally, the company is advancing SNX-1012, a treatment aimed at alleviating oral mucositis in patients with solid tumors. Through its innovative approach to drug development, Serenex aims to address significant unmet medical needs in various disease areas.
BioVigilant Systems
Series A in 2006
BioVigilant Systems specializes in advanced microbial detection technology aimed at enhancing environmental monitoring across various sectors, including pharmaceuticals, biotechnology, healthcare, and environmental applications. The company's innovative instantaneous microbial detection (IMD) systems provide real-time analysis of particulate count, size, and biological status without the need for staining, reagents, or extended waiting periods. This optically-based technology streamlines the monitoring process, minimizing human intervention and improving efficiency in critical environments.
CoLucid Pharmaceuticals
Series A in 2006
CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.